Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Healthcare
Quantum BioPharma Ltd, formerly FSD Pharma Inc., is a biotechnology company. It operates in two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of its two primary drug candidates, consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. Its Strategic Investments segment is focused on... see more

Recent & Breaking News (CSE:QNTM)

Quantum BioPharma Closes Private Placement Offering

Newsfile 3 days ago

Quantum BioPharma to run multiple sclerosis progression study

Jocelyn Aspa 7 days ago

Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis

Accesswire 7 days ago

Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements

Accesswire 10 days ago

Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can "own NOW and what's NEXT"

Accesswire August 30, 2024

Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update

Accesswire August 23, 2024

FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol "QNTM"

Newsfile August 15, 2024

FSD Pharma Announces Share Consolidation and Name Change

Newsfile August 9, 2024

FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team

Accesswire August 9, 2024

24/7 Market News Publishes Report Covering Functional Beverage Market, Featuring FSD Pharma

Newsfile July 25, 2024

FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders

Newsfile July 23, 2024

24/7 Market News Publishes Report Covering Biotech Developments, Featuring FSD Pharma

Newsfile July 23, 2024

FSD Pharma Files Amended and Restated Material Change Report

Newsfile July 4, 2024

FSD Pharma provides Corporate Update

Accesswire June 28, 2024

FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.

Accesswire June 28, 2024

FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia

Accesswire June 27, 2024

FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications

Accesswire June 13, 2024

FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication

Accesswire June 4, 2024

FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest

Accesswire May 31, 2024

FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication

Accesswire May 28, 2024